653 - Japanese cohort study of first line chemotherapy (CT) for metastatic colorectal cancer (mCRC) containing fluoropyrimidine, oxaliplatin and bevacizum...

Date 28 September 2012
Event ESMO Congress 2012
Session Publication Only
Topics Anticancer agents
Colon and Rectal Cancer
Biological therapy
Presenter Keisei Taku
Authors K. Taku1, K. Ohata1, K. Yamazaki2, G. Nishikawa1, M. Watanabe3, S. Sato3, T. Oshima3, H. Hirano1, T. Amano4, Y. Ohashi5
  • 1Division Of Medical Oncology, Shizuoka General Hospital, 420-8527 - Shizuoka/JP
  • 2Gastrointestinal Oncology And Endoscop, Shizuoka Cancer Center, JP-411-8777 - Shizuoka/JP
  • 3Division Of Surgery, Shizuoka General Hospital, 420-8527 - Shizuoka/JP
  • 4Medical Oncology, Hokkaido University Graduate School of Medicine, 060-8638 - Sapporo/JP
  • 5Department Of Biostatistics, School Of Public Health, University of Tokyo, 113-8655 - Tokyo/JP



An observational cohort study plays a crucial role to understand the current status of clinical practice and can be utilized as database for multi-purpose outcome research. Such database is available in Europe and the United States based on several cohort studies especially in mCRC, while there is no database available including treatments for mCRC patients in Japan.


According to the Japanese Ethical Guideline for Epidemiologic Study, we planned and conducted a large cohort study in Japan. Data from more than 1000 patients were planned to be collected between October 2010 and September 2011 with 2-year follow-up period. Enrollment criteria included documented mCRC and first line CT containing fluoropyrimidine, oxaliplatin and bevacizumab, started treatment in or after January 2010, tumor response image assessment available, safety assessment available and able to offer information outside of originally enrolled studies. The primary objectives are to evaluate overall survival, liver resection rate, R0 liver resection rate; the secondary objectives are to evaluate response rate, progression-free survival, sub-group analysis by treatment regimens and by KRAS gene status, and safety.


From October 2010 to September 2011, 1270 patients were recruited from 132 centers in Japan. The background of patients were as the following; male/female, 766/504; median age of 65 (range, 21-89); ECOG PS 0/1/2/3, 1045/203/17/5; FOLFOX/ CapeOX/ others with bevacizumab, 563/667/40, KRAS gene status at baseline was wild/mutant/unknown, 286/223/761; CEA median of 13.8 (range, 0.0–90055.0 ng/ml) and comorbidity no/yes, 798/472.


We have started the large Japanese cohort study which investigates first line CT containing fluoropyrimidine, oxaliplatin and bevacizumab for metastatic colorectal cancer. We performed a preplanned interim analysis. We present the first report of 6-month efficacy and safety data on 500 patients at the ESMO 2012 Congress. The final results will be available in 2013.

This study is sponsored by the Public Health Research Center Foundation CSPOR in Japan.


All authors have declared no conflicts of interest.